Targeted therapies for gastric cancer: Current status

Drugs

Volumn 71, Issue 11, 2011, Pages 1367-1384

  Yoong, Jaclyn ^a   Michael, Michael ^b   Leong, Trevor ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aspirin; Capsaicin; Clopidogrel; Corticosteroids; Diclofenac; Drug interactions; Eltenac; Felbinac; Fenbufen; Ibuprofen; Ketoprofen; Naproxen; Nonsteroidal anti inflammatories; Osteoarthritis; Paracetamol; Piroxicam; Proton pump inhibitors; Salicylates; Serotonin uptake inhibitors; Topical; Warfarin.

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; FORETINIB; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; METHOTREXATE; NEVAXAR; OXALIPLATIN; PACLITAXEL; SELUMETINIB; SORAFENIB; SUNITINIB; TEGAFUR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL; VANDETANIB;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; ESOPHAGITIS; ESOPHAGUS CANCER; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; POSTOPERATIVE CARE; PROGNOSIS; RASH; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 79961141540     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11592530-000000000-00000     Document Type: Review

References (177)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006 May 10; 24 (14): 2137-50. (Pubitemid 46655601)
2. Altekruse SF, Kosary CL, KrapchoM, et al. SEER cancer statistics review, 1975-2007 [online]. Available from URL: http://seer.cancer.gov/csr/1975-2007/ (based on November 2009 SEER data submission, posted to the SEER website, 2010) [Accessed 2010 Nov 22].
3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 Suppl. 2: ii31-6. (Pubitemid 36874136)
4. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010 Nov; 26 (6): 640-6.
5. Mlkvy P. Multimodal therapy of gastric cancer. Dig Dis 2010; 28 (4-5): 615-8.
6. Gianni L, Panzini I, Tassinari D, et al. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001 Aug; 12 (8): 1178-80.
7. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol 1993 Aug; 11 (8): 1441-7. (Pubitemid 23228247)
8. Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40 (2-3): 309-26. (Pubitemid 32588125)
9. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials-a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000 Jul; 11 (7): 837-43.
10. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002 Jan-Feb; 88 (1): 21-7. (Pubitemid 34269794)
11. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: ametaanalysis. JAMA 2010 May 5; 303 (17): 1729-37.
12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001 Sep 6; 345 (10): 725-30.
13. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 Jul 6; 355 (1): 11-20.
14. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999 Apr; 80 (1-2): 269-72. (Pubitemid 29210117)
15. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997 Jan; 15 (1): 261-7. (Pubitemid 27020582)
16. Icli F, Celik I, Aykan F, et al. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 1998 Dec 15; 83 (12): 2475-80. (Pubitemid 29019565)
17. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000 Jul; 18 (14): 2648-57. (Pubitemid 30465650)
18. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007 Aug 1; 25 (22): 3210-6. (Pubitemid 47325603)
19. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007 Aug 1; 25 (22): 3205-9. (Pubitemid 47333732)
20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006 Nov 1; 24 (31): 4991-7. (Pubitemid 46631401)
21. Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002 Jun; 13 (5): 497-503. (Pubitemid 34624633)
22. Kang GH, Kim GS, Lee HR, et al. A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2008 Sep; 40 (3): 106-10.
23. Kang HJ, Chang HM, Kim TW, et al. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008 Jan 29; 98 (2): 316-22. (Pubitemid 351161266)
24. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000 Aug; 83 (4): 458-62. (Pubitemid 30487857)
25. Hejna M, Raderer M, Zacherl J, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. Anticancer Drugs 2008 Jun; 19 (5): 535-9. (Pubitemid 351559607)
26. Kim JG, Sohn SK, Chae YS, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 2008 Feb 12; 98 (3): 542-6. (Pubitemid 351214521)
27. Kim YS, Hong J, Sym SJ, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat Mar 2010; 42 (1): 24-9.
28. Lee HH, Hur H, Kim SH, et al. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat Mar 2010; 42 (1): 18-23.
29. Luo HY, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010; 56 (2): 94-100.
30. RichardsD,McCollumD,Wilfong L, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 2008 Jan; 19 (1): 104-8.
31. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008 Mar 20; 26 (9): 1435-42.
32. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008 Jan 3; 358 (1): 36-46.
33. Kanat O, Evrensel T, Manavoglu O, et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori 2003 Jul-Aug; 89 (4): 405-7. (Pubitemid 37279923)
34. Kohne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003 Sep 15; 89 (6): 997-1001. (Pubitemid 37239201)
35. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002 Feb 1; 94 (3): 641-6. (Pubitemid 34132291)
36. Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2007 Sep 3; 97 (5): 593-7. (Pubitemid 47339888)
37. Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009 Mar; 20 (3): 475-80.
38. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004 Jan; 15 (1): 64-9. (Pubitemid 38145530)
39. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006 May 22; 94 (10): 1407-11. (Pubitemid 43772274)
40. Burge ME, Smith D, Topham C, et al. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 2006 May 8; 94 (9): 1281-6.
41. Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003 Sep; 14 (8): 645-50. (Pubitemid 37303932)
42. Gubanski M, Johnsson A, Fernebro E, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010 Aug; 13 (3): 155-61.
43. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008 Aug; 19 (8): 1450-7.
44. Baize N, Abakar-Mahamat A, Mounier N, et al. Phase II study of paclitaxel combined with capecitabine as secondline treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 2009 Aug; 64 (3): 549-55.
45. Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005 Apr; 28 (2): 188-94. (Pubitemid 40514433)
46. Kim JG, Sohn SK, Kim DH, et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68 (2-3): 190-5. (Pubitemid 41158975)
47. Kang YK, Ryu MH, Yoo C, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011; 67 (6): 1435-43.
48. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000 Nov; 18 (4): 331-42.
49. Shirasaka T, Yamamitsu S, Tsuji A, et al. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000 Nov; 18 (4): 315-29.
50. Chao Y, Li CP, Chao TY, et al. An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer 2006 Jul 17; 95 (2): 159-63. (Pubitemid 44055884)
51. Inokuchi M, Yamashita T, Yamada H, et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006 Apr 24; 94 (8): 1130-5.
52. Jeen YT, Yoon SY, Shin SW, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001 Jun 15; 91 (12): 2288-93. (Pubitemid 32552814)
53. Kim YH, Cheong SK, Lee JD, et al. Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996 Apr; 19 (2): 212-6. (Pubitemid 26108231)
54. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000 Apr; 58 (3): 191-7. (Pubitemid 30189900)
55. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008 Mar; 9 (3): 215-21.
56. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003 Dec 15; 89 (12): 2207-12. (Pubitemid 38168001)
57. Mochiki E, Ohno T, Kamiyama Y, et al. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006 Dec 18; 95 (12): 1642-7. (Pubitemid 44950789)
58. Narahara H, Fujitani K, Takiuchi H, et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74 (1-2): 37-41. (Pubitemid 351915008)
59. Oh SC, Park KH, Choi IK, et al. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br J Cancer 2005 Mar 14; 92 (5): 827-31. (Pubitemid 40462625)
60. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003 Jan 1; 21 (1): 54-9.
61. Park SR, Kong SY, Rhee J, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 2011 Apr; 22 (4): 890-6.
62. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999 Oct; 57 (3): 202-10. (Pubitemid 29481693)
63. Woo IS, Moon DH, Shim BY, et al. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol 2005 Jan; 35 (1): 13-7. (Pubitemid 40450549)
64. Yamaguchi K, Shimamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006 Jun 19; 94 (12): 1803-8. (Pubitemid 43884569)
65. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006 Jun 1; 12 (11 Pt 1): 3402-7.
66. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006 Feb 1; 24 (4): 663-7. (Pubitemid 46630431)
67. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010 Mar 20; 28 (9): 1547-53.
68. Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer: a trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003 Jun; 39 (9): 1264-70. (Pubitemid 36579198)
69. Ravaud A, Borner M, Schellens JH, et al. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer: an Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 2001 Sep; 37 (13): 1642-7. (Pubitemid 32778610)
70. Boonstra J, Rijken P, Humbel B, et al. The epidermal growth factor. Cell Biol Int 1995 May; 19 (5): 413-30.
71. Pai R, Tarnawski A. Signal transduction cascades triggered by EGF receptor activation: relevance to gastric injury repair and ulcer healing. Dig Dis Sci 1998 Sep; 43 (9 Suppl.): 14-22S. (Pubitemid 28433944)
72. Patel D, Bassi R, Hooper A, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009 Jan; 34 (1): 25-32.
73. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010 Mar 1; 16 (5): 1509-19.
74. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001 Oct; 28 (5 Suppl. 16): 56-66. (Pubitemid 33065111)
75. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010 May; 36 (3): 235-48.
76. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008 Feb; 19 (2): 99-113.
77. Yasui W, Hata J, Yokozaki H, et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 1988 Feb 15; 41 (2): 211-7. (Pubitemid 18061145)
78. Yonemura Y, Sugiyama K, Fujimura T, et al. Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 1989; 46 (3): 158-61.
79. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006 Aug; 33 (4): 369-85. (Pubitemid 44142736)
80. Luo HY, Wei W, Shi YX, et al. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep 2010 Jun; 23 (6): 1735-45.
81. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008 Feb 1; 70 (2): 391-5.
82. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007 Mar; 18 (3): 510-7. (Pubitemid 46359631)
83. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010 Feb 2; 102 (3): 500-5.
84. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011; 29 (2): 366-73.
85. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009 Oct 20; 101 (8): 1261-8.
86. Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22 (6): 1358-66.
87. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001 May; 7 (5): 1459-65. (Pubitemid 32708703)
88. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001 Oct; 7 (10): 2958-70. (Pubitemid 32963812)
89. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [published erratum appears in J Clin Oncol 2004; 22 (23): 4811]. J Clin Oncol 2003 Jun 15; 21 (12): 2237-46. (Pubitemid 46621858)
90. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 Oct 22; 290 (16): 2149-58. (Pubitemid 37432975)
91. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361 (10): 947-57.
92. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32. (Pubitemid 41058344)
93. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 May 20; 25 (15): 1960-6. (Pubitemid 46972777)
94. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009 Jun; 10 (5): 470-81.
95. Park JK, Lee SH, Kang JH, et al. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 2004 Sep; 15 (8): 809-18.
96. Kishida O, Miyazaki Y, Murayama Y, et al. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 2005 Jun; 55 (6): 584-94. (Pubitemid 40674634)
97. Doi T, Koizumi W, Siena S et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer [abstract no. 1036]. Proc Am Soc Clin Oncol 2003; 22: 258.
98. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006 Oct 20; 24 (30): 4922-7. (Pubitemid 46630921)
99. Koeppen HK, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001 Feb; 38 (2): 96-104. (Pubitemid 32194449)
100. Jaehne J, Urmacher C, Thaler HT, et al. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118 (6): 474-9.
101. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235 (4785): 177-82. (Pubitemid 17231334)
102. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32 (1-2): 57-65.
103. Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005 Nov-Dec; 91 (6): 513-21. (Pubitemid 43251123)
104. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001; 12 Suppl. 1: S35-41. (Pubitemid 32750583)
105. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007 Jul 5; 357 (1): 39-51. (Pubitemid 47026733)
106. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl JMed 2005 Oct 20; 353 (16): 1659-72. (Pubitemid 41464705)
107. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353 (16): 1673-84. (Pubitemid 41464706)
108. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6; 369 (9555): 29-36. (Pubitemid 46039831)
109. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 Sep; 17 (9): 2639-48. (Pubitemid 29415219)
110. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 Mar 15; 344 (11): 783-92. (Pubitemid 32222155)
111. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 Feb 1; 20 (3): 719-26. (Pubitemid 34111379)
112. Seidman A, Hudis C, PierriMK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002 Mar 1; 20 (5): 1215-21. (Pubitemid 34177427)
113. Matsui Y, Inomata M, TojigamoriM, et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005 Sep; 27 (3): 681-5.
114. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007 May; 59 (6): 795-805. (Pubitemid 46440603)
115. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008 Jan; 32 (1): 89-95. (Pubitemid 351176065)
116. Li XL, Yi SQ, Xu JM, et al. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest 2010 Dec; 28 (10): 1038-47.
117. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Aug 28; 376 (9742): 687-97.
118. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 Dec; 1 (2): 85-94.
119. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 Dec 28; 355 (26): 2733-43. (Pubitemid 46021510)
120. Kim JW, Kim HP, Im SA, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008 Dec 18; 272 (2): 296-306.
121. Tanizaki J, Okamoto I, Takezawa K, et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010 May; 9 (5): 1198-207.
122. Iqbal S,Goldman B, Fengolio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. Epub 2011 May 20.
123. GlaxoSmithKline. LOGiC-Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: a phase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib. [Clin icalTrials.gov identifier NCT00680901]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 17].
124. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 Jan 3; 82 (1): 4-6. (Pubitemid 20020880)
125. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36 (2): 127-37.
126. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999 Sep; 56 (3): 794-814. (Pubitemid 29411709)
127. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106 (4): 148-56. (Pubitemid 34124153)
128. Yamamoto S, Yasui W, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 1998 Jul; 48 (7): 499-506. (Pubitemid 28341085)
129. Kimura H, Konishi K, Nukui T, et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 2001 Jan; 76 (1): 31-6. (Pubitemid 32128360)
130. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996 Mar 1; 77 (5): 858-63. (Pubitemid 26061277)
131. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998 Dec; 34 (13): 2041-5. (Pubitemid 28546939)
132. Maeda K, Kang SM, Onoda N, et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 1998 Nov-Dec; 55 (6): 594-9. (Pubitemid 28479121)
133. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000 May 29; 153 (1-2): 7-12. (Pubitemid 30209837)
134. Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010; 15 (8): 819-25.
135. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al. Safety of bevacizumab in patients with advanced cancer: a metaanalysis of randomized controlled trials. Oncologist 2010; 15 (11): 1179-91.
136. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract no. LBA4007]. J Clin Oncol 2010; 28 Suppl.: 18s.
137. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006 Nov 20; 24 (33): 5201-6. (Pubitemid 46631363)
138. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010 Oct; 21 (10): 1999-2004.
139. Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract no. 4552]. J Clin Oncol 2008; 26 (15S May 20 Suppl.): 4552.
140. Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial [abstract no. 4512]. J Clin Oncol 2009; 27 (15S May 20 Suppl.): 4512.
141. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008 Aug; 13 (8): 845-58.
142. Tesei A, Leonetti C, Zupi G, et al. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med. Epub 2009 Dec 8.
143. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. Epub 2010 Sep 14.
144. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010 Jun 20; 28 (18): 2947-51.
145. Cortes-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol 2009 Jun; 11 (6): 349-55.
146. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. Epub 2010 May 12.
147. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009 Apr; 14 (4): 378-90.
148. Lyros O, Mueller A, Heidel F, et al. Analysis of antiproliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 2010 Sep 1; 127 (5): 1197-208.
149. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004 Sep; 3 (9): 1041-8. (Pubitemid 39295001)
150. Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2: 45.
151. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007 Apr 15; 120 (8): 1803-10. (Pubitemid 46399369)
152. An JY, Kim KM, Choi MG, et al. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 2010 Jun 15; 126 (12): 2904-13.
153. Taguchi F, Kodera Y, Katanasaka Y, et al. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs. Epub 2010 Jun 8.
154. Cejka D, Preusser M, Fuereder T, et al. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 2008 Nov-Dec; 28 (6A): 3801-8.
155. Lee KH, Hur HS, Im SA, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010 Dec 18; 299 (1): 22-8.
156. Matsuzaki T, Yashiro M, Kaizaki R, et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009 Dec; 100 (12): 2402-10.
157. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, et al. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 2010 Oct 28; 296 (2): 249-56.
158. Yamada Y, Doi T, Muro K, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010 Apr 10; 28 (11): 1904-10.
159. GRANITE-1: safety and efficacy of RAD001 (Everolimus) monotherapy plus best supportive care in patients with advanced gastric cancer (AGC). [ClinicalTrials.gov identifier NCT00879333]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 5].
160. GRANITE-2: a randomized, double blind study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma after prior chemotherapy (AIO-STO-0111). [ClinicalTrials.gov identifier NCT01248403]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 5].
161. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999 May 1; 85 (9): 1894-902. (Pubitemid 29202761)
162. Jhawer MP, Kindler HL, Wainberg ZA, et al. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. J Clin Oncol 2008; 26 (15S): 4572.
163. Jhawer M, Kindler HL, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study [abstract]. J Clin Oncol 2009; 27 (15S): 4502.
164. Gollob JA,Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006 Aug; 33 (4): 392-406. (Pubitemid 44142735)
165. Yang S, Ngo VC, Lew GB, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009 Sep; 8 (9): 2537-45.
166. Yoon YK, Kim HP, Han SW, et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009 Sep; 8 (9): 2526-36.
167. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000 Mar 1; 92 (5): 376-87. (Pubitemid 30154819)
168. Jung C, Motwani M, Kortmansky J, et al. The cyclindependent kinase inhibitor flavopiridol potentiates gammairradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003 Dec 1; 9 (16 Pt 1): 6052-61. (Pubitemid 38018093)
169. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with downregulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001 Aug; 7 (8): 2527-36. (Pubitemid 32751659)
170. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999 Jul; 5 (7): 1876-83. (Pubitemid 29334472)
171. Motwani M, Rizzo C, Sirotnak F, et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003 Jun; 2 (6): 549-55.
172. Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009 Dec 1; 15 (23): 7405-11.
173. Schwartz GK, Farsi K, Maslak P, et al. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997 Sep; 3 (9): 1467-72. (Pubitemid 27431552)
174. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002 Dec; 50 (6): 465-72. (Pubitemid 35435525)
175. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001 Apr 1; 19 (7): 1985-92. (Pubitemid 32702543)
176. Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010 Mar 1; 16 (5): 1662-72.
177. Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer Feb 15; 126 (4): 1004-16